The Latest Breaking News from Vyvgart

Argenx stock tumbled Thursday after the company's autoimmune disease drug, Vyvgart, beat first-quarter sales forecasts — but not by enough.

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.

Argenx is up around 40% in 2023. On Thursday, the company reported second-quarter revenue ballooning 230% as sales of its lone product ramp up.

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases.  According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Argenx SE's (NASDAQ:ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint.  The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. Patients were heavily pretreated. A higher proportion of patients with chronic ITP receiving VYVGART (17/78; 21.8%) than placebo…

Argenx SE (NASDAQ: ARGX) announced 

Argenx SE (NASDAQ: ARGX) ) has